Dorota Religa and Robert Perneczky walk us through the most exciting findings from the AD/PD™ and CONy 2024 conferences. Their discussion focuses on existing and emerging biomarkers and new amyloid-targeting therapies in Alzheimer's disease.
12-04-2024 | Alzheimer's Disease | Panel Discussion | Article | Supported by: Lilly
Experts in Conversation